Literature DB >> 33382123

Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases.

Bin Xu1, Albert J H Suurmeijer2, Narasimhan P Agaram1, Lei Zhang1, Cristina R Antonescu1.   

Abstract

AIMS: Primary intraosseous rhabdomyosarcoma (RMS) is a rare entity defined by EWSR1/FUS-TFCP2 or, less commonly, MEIS1-NCOA2 fusions. The lesions often show a hybrid spindle and epithelioid phenotype, frequently coexpress myogenic markers, ALK, and cytokeratin, and show a striking propensity for the pelvic and craniofacial bones. The aim of this study was to investigate the clinicopathological and molecular features of 11 head and neck RMSs (HNRMSs) characterised by the genetic alterations described in intraosseous RMS. METHODS AND
RESULTS: The molecular abnormalities were analysed with fluorescence in-situ hybridisation and/or targeted RNA/DNA sequencing. Seven cases had FUS-TFCP2 fusions, four had EWSR1-TFCP2 fusions, and none had MEIS1-NCOA2 fusions. All except one case were intraosseous, affecting the mandible (n = 4), maxilla (n = 3), and skull (n = 3). One case occurred in the superficial soft tissue of the neck. The median age was 29 years (range, 16-74 years), with an equal sex distribution. All tumours showed mixed epithelioid and spindle morphology. Immunohistochemical coexpression of desmin, myogenin, MyoD1, ALK, and cytokeratin was seen in most cases. An intragenic ALK deletion was seen in 43% of cases. Regional and distant spread were seen in three and four patients, respectively. Two patients died of their disease.
CONCLUSIONS: We herein present the largest series of HNRMSs with TFCP2 fusions to date. The findings show a strong predilection for the skeleton in young adults, although we also report an extraosseous case. The tumours are characterised by a distinctive spindle and epithelioid phenotype and a peculiar immunoprofile, with coexpression of myogenic markers, epithelial markers, and ALK. They are associated with a poor prognosis, including regional or distant spread and disease-related death.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  ALK; EWSR1-TFCP2 fusion; FUS-TFCP2 fusion; intraosseous rhabdomyosarcoma; rhabdomyosarcoma

Mesh:

Substances:

Year:  2021        PMID: 33382123      PMCID: PMC8243398          DOI: 10.1111/his.14323

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   7.778


  24 in total

1.  Rhabdomyosarcoma with FUS re-arrangement: additional case in support of a novel subtype.

Authors:  Daniel D Wong; Chris van Vliet; Andrew Gaman; Tindaro Giardina; Benhur Amanuel
Journal:  Pathology       Date:  2018-11-23       Impact factor: 5.306

Review 2.  The current landscape of rhabdomyosarcomas: an update.

Authors:  Julia Leiner; François Le Loarer
Journal:  Virchows Arch       Date:  2019-11-06       Impact factor: 4.064

3.  TFCP2 Is Required for YAP-Dependent Transcription to Stimulate Liver Malignancy.

Authors:  Xiao Zhang; Fenyong Sun; Yongxia Qiao; Weisheng Zheng; Ya Liu; Yan Chen; Qi Wu; Xiangfan Liu; Guoqing Zhu; Yuxin Chen; Yongchun Yu; Qiuhui Pan; Jiayi Wang
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

4.  Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype.

Authors:  Narasimhan P Agaram; Lei Zhang; Yun-Shao Sung; Marcela S Cavalcanti; Dianne Torrence; Leonard Wexler; Glenn Francis; Scott Sommerville; David Swanson; Brendan C Dickson; Albert J H Suurmeijer; Richard Williamson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2019-05       Impact factor: 6.394

Review 5.  TFCP2/TFCP2L1/UBP1 transcription factors in cancer.

Authors:  Grzegorz Kotarba; Ewa Krzywinska; Anna I Grabowska; Agnieszka Taracha; Tomasz Wilanowski
Journal:  Cancer Lett       Date:  2018-02-07       Impact factor: 8.679

6.  A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.

Authors:  Rita Alaggio; Lei Zhang; Yun-Shao Sung; Shih-Chiang Huang; Chun-Liang Chen; Gianni Bisogno; Angelica Zin; Narasimhan P Agaram; Michael P LaQuaglia; Leonard H Wexler; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.

Authors:  Narasimhan P Agaram; Michael P LaQuaglia; Rita Alaggio; Lei Zhang; Yumi Fujisawa; Marc Ladanyi; Leonard H Wexler; Cristina R Antonescu
Journal:  Mod Pathol       Date:  2018-09-04       Impact factor: 7.842

8.  Head and Neck Mesenchymal Neoplasms With GLI1 Gene Alterations: A Pathologic Entity With Distinct Histologic Features and Potential for Distant Metastasis.

Authors:  Bin Xu; Koping Chang; Andrew L Folpe; Yu-Chien Kao; Shiuan-Li Wey; Hsuan-Ying Huang; Anthony J Gill; Lisa Rooper; Justin A Bishop; Brendan C Dickson; Jen-Chieh Lee; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.298

9.  Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence.

Authors:  Jennifer L S Willoughby; Kelly George; Mark P Roberto; Hang Gyeong Chin; Patrick Stoiber; Hyunjin Shin; Chandra Sekhar Pedamallu; Scott E Schaus; Kevin Fitzgerald; Jagesh Shah; Ulla Hansen
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

10.  Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.

Authors:  Guo Zhu; Ryma Benayed; Caleb Ho; Kerry Mullaney; Purvil Sukhadia; Kelly Rios; Ryan Berry; Brian P Rubin; Khedoudja Nafa; Lu Wang; David S Klimstra; Marc Ladanyi; Meera R Hameed
Journal:  Mod Pathol       Date:  2018-11-21       Impact factor: 7.842

View more
  7 in total

Review 1.  Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022. Emerging Bone and Soft Tissue Neoplasms in the Head and Neck Region.

Authors:  Bin Xu
Journal:  Head Neck Pathol       Date:  2022-03-21

2.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Odontogenic and Maxillofacial Bone Tumours.

Authors:  Marilena Vered; John M Wright
Journal:  Head Neck Pathol       Date:  2022-03-21

3.  Clinicopathologic features and outcome of head and neck mucosal spindle cell squamous cell carcinoma.

Authors:  Carlos N Prieto-Granada; Bin Xu; Bayan Alzumaili; Mohamed Rizwan Haroon Al Rasheed; Antoine Eskander; Danny Enepekides; Snehal G Patel; Todd M Stevens; Snjezana Dogan; Ronald Ghossein; Nora Katabi
Journal:  Virchows Arch       Date:  2021-05-12       Impact factor: 4.535

Review 4.  Evolving classification of rhabdomyosarcoma.

Authors:  Narasimhan P Agaram
Journal:  Histopathology       Date:  2022-01       Impact factor: 7.778

5.  Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas.

Authors:  Alessandro De Vita; Silvia Vanni; Valentina Fausti; Claudia Cocchi; Federica Recine; Giacomo Miserocchi; Chiara Liverani; Chiara Spadazzi; Massimo Bassi; Manlio Gessaroli; Angelo Campobassi; Giovanni De Luca; Federica Pieri; Anna Farnedi; Eugenia Franchini; Anna Ferrari; Chiara Domizio; Enrico Cavagna; Lorena Gurrieri; Alberto Bongiovanni; Nada Riva; Sebastiano Calpona; Giandomenico Di Menna; Silvia Angela Debonis; Toni Ibrahim; Laura Mercatali
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

Review 6.  Update of Key Clinical, Histological and Molecular Features of Malignant Bone Tumours Arising in the Craniofacial Skeleton.

Authors:  Simon Haefliger; Vanghelita Andrei; Daniel Baumhoer
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

Review 7.  Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment.

Authors:  Mario Turri-Zanoni; Giacomo Gravante; Paolo Castelnuovo
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.